|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2400094812 |
|
最近更新日期: Date of Last Refreshed on: |
2024-12-27 15:57:47 |
|
注册时间: Date of Registration: |
2024-12-27 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
老年前列腺癌合并衰弱患者多模式预康复干预方案的构建及应用 |
|
Public title: |
Construction and application of multi-mode pre-rehabilitation intervention scheme for on frailty in elderly patients with prostate cancer |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
老年前列腺癌合并衰弱患者多模式预康复干预方案的构建及应用 |
|
Scientific title: |
Construction and application of multi-mode pre-rehabilitation intervention scheme for on frailty in elderly patients with prostate cancer |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
王楠 |
研究负责人: |
李娜 |
|
Applicant: |
Nan Wang |
Study leader: |
Na Li |
|
申请注册联系人电话: Applicant telephone: |
+86 178 6152 3827 |
研究负责人电话:
Study leader's |
+86 159 6003 8428 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
wangnan0125689@163.com |
研究负责人电子邮件: Study leader's E-mail: |
nali1028@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
福建省福州市台江区交通路88号 |
研究负责人通讯地址: |
福建省福州市东街134号 |
|
Applicant address: |
No.88, jiaotong Road, Fuzhou, Fujian province, China |
Study leader's address: |
134 Dongjie Road, Fuzhou, Fujian province, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
福建医科大学护理学院 |
||
|
Applicant's institution: |
School of Nursing, Fujian Medical University |
||
|
研究负责人所在单位: |
福建省立医院 |
||
|
Affiliation of the Leader: |
Fujian Provincial Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
伦理科研第(K2024-03-008)号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
福建省立医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of Fujian Provincial Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-03-29 00:00:00 | ||
|
伦理委员会联系人: |
练发杨 |
||
|
Contact Name of the ethic committee: |
Fayang Lian |
||
|
伦理委员会联系地址: |
福建省福州市东街134号 |
||
|
Contact Address of the ethic committee: |
134 Dongjie Road, Fuzhou, Fujian province, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 591 8821 6023 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
福建省立医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Fujian Provincial Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
福建省福州市东街134号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
134 Dongjie Road, Fuzhou, Fujian province, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
福建省卫健委科技计划项目 |
||||||||||||||||||||||
|
Source(s) of funding: |
Fujian Provincial Health Commission science and technology plan project |
||||||||||||||||||||||
|
研究疾病: |
前列腺癌 |
||||||||||||||||||||||
|
Target disease: |
prostatic cancer |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
评价多模式预康复方案对改善患者衰弱状况、身体功能等术后结局的有效性 |
||||||||||||||||||||||
|
Objectives of Study: |
To evaluate the effectiveness of multi-mode pre-rehabilitation program in improving frailty, physical function and other postoperative outcomes |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.年龄>=60岁; 2.经前列腺穿刺活检或前列腺癌术后病理诊断为前列腺癌者且择期手术的患者; 3.G-8评分<14分; 4.具备基本沟通交流、理解能力,能够完成量表评估; 5.知情同意,自愿参加本研究。 |
||||||||||||||||||||||
|
Inclusion criteria |
1. Age>=60 years; 2. Patients with prostate cancer diagnosed by prostate biopsy or prostate cancer after surgery and elective surgery; 3. G-8 score< 14 points; 4. Have basic communication and comprehension skills, and be able to complete the scale assessment; 5. Informed consent, voluntary participation in this study. |
||||||||||||||||||||||
|
排除标准: |
1.多原发癌或转移癌; 2.因复发入院的前列腺癌患者; 3.禁忌进行体育运动训练或心肺运动试验(CPET)的患者; 4.患有严重躯体疾病、药物或酒精成瘾、抑郁等精神疾病、无法理解并配合完成研究者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Multiple primary cancers or metastatic cancers; 2. Prostate cancer patients admitted to the hospital due to recurrence; 3. Patients who are contraindicated to undergo sports training or cardiopulmonary exercise test (CPET); 4. Those who have serious physical illness, drug or alcohol addiction, depression and other mental illnesses that are unable to understand and cooperate with the completion of the study. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-03-29 00:00:00至 To 2024-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2024-03-29 00:00:00 至 To 2024-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男性 |
Gender: |
Male |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
使用随机表进行随机,按照研究方案进行随机,随机内容以随机信封的方式实施,随机信封保存于研究中心。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Random table was used for randomization, randomization was carried out according to the research plan, and the randomization content was carried out in the way of random envelope, which was kept in the research center. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
本研究只对研究资料的收集者和统计分析者保持盲法。 |
|
Blinding: |
In this study, only data collectors and statistical analysts were kept blind. |
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
研究结束后,通过ResMan(www.medresman.org.cn)方式共享 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
After the end of the study, it was shared by ResMan (www.medresman.org.cn). |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
CRF;EDC |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
CRF;EDC |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |